About 10 Trademarks found that are owned by Ra Pharmaceuticals Inc.

The mark consists of the word "ZILBRYSQ", where the letters "ZILBRYS" of "ZILBRYSQ" are in a blue font and letter "Q" fades from orange to red to blue in a clockwise direction starting from the bottom of the "Q" and ending at the tail of the "Q".

"PHARMACEUTICALS"

Pharmaceutical preparations, for human use, for the prevention and treatment of myasthenia gravis

Syringes for injections; Syringes for medical purposes; Syringes for medical purposes sold empty which may be filled with pharmaceutical preparations, for human use, for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, myasthenia gravis, an inflammatory indication, a wound, a burn, an autoimmune indication, a pulmonary indication, a cardiovascular indication, a neurological indication, a kidney-related indication, a diabetes-related indication, an ocular indication, and a pregnancy-related indication

Pharmaceutical preparations, for human use, for the prevention and treatment of disorders of metabolism, the nervous system, the immune system, the cardio-vascular system, the respiratory system, the musculo-skeletal system, and the genitourinary system; for the treatment of fibrotic and inflammatory disorders; for use in dermatology, nephrology, hepatology, rheumatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; as anti-viral, anti-bacterial, or anti-fungal agents; none of the foregoing for prevention or treatment of rheumatoid arthritis

"PHARMA"

"PHARMA"

Pharmaceutical preparations, for human use, for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, myasthenia gravis, an inflammatory disorder, a wound, a burn, an autoimmune disorder, a pulmonary disorder, a cardiovascular disorder, a neurological disorder, a kidney-related disorder, a diabetes-related disorder, an ocular disorder, and a pregnancy-related disorder; Pharmaceutical preparations, for human use, for the prevention and treatment of disorders of metabolism, the nervous system, the immune system, the cardio-vascular system, the respiratory system, the musculo-skeletal system, and the genitourinary system; Pharmaceutical preparations for the treatment of fibrotic and inflammatory disorders; Pharmaceutical preparations for use in dermatology, nephrology, hepatology, rheumatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations as anti-viral, anti-bacterial, or anti-fungal agents

The wording ZILBRYSQ has no meaning in a foreign language.

Pharmaceutical research and development in the field of peptides and/or peptidomimetics; the foregoing services not related to rheumatoid arthritis

Pharmaceutical research and development in the field of peptides and/or peptidomimetics; the foregoing services not related to rheumatoid arthritis

The mark consists of the word "ZILUCOPLAN" in gray under the word "ZILBRYSQ", where the letters "ZILBRYS" of "ZILBRYSQ" are in a blue font and letter "Q" fades from orange to red to blue in a clockwise direction starting from the bottom of the "Q" and ending at the tail of the "Q".

The wording "ZILBRYSQ ZILUCOPLAN" has no meaning in a foreign language.